Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003238 | 0.85 | PGR (0.47) | BACE1CTSDPIK3CDGRIN1GRIN2B | |
| SCHEMBL3031160 | 0.84 | SLC6A7 (0.38) | BACE1CTSDGRIN1GRIN2BSCN9A | |
| SCHEMBL1949510 | 0.84 | BACE1 (0.41) | BACE1CTSDMAOBGRIN1GRIN2B | |
| SCHEMBL3037745 | 0.84 | GRIN1 (0.39) | BACE1CTSDGRIN1GRIN2B | |
| SCHEMBL3040774 | 0.83 | GRIN1 (0.40) | BACE1CTSDGRIN1GRIN2BSCN9A | |
| SCHEMBL2785547 | 0.82 | SLC11A2 (0.44) | BACE1CTSDGRIN1GRIN2BSCN9A | |
| SCHEMBL3037421 | 0.81 | GRIN1 (0.40) | BACE1CTSDGRIN1GRIN2B | |
| SCHEMBL3021656 | 0.81 | GRIN1 (0.45) | BACE1CTSDGRIN1GRIN2BSCN9A | |
| SCHEMBL1950808 | 0.81 | ASIC3 (0.39) | BACE1CTSDMAOBGRIN1GRIN2B | |
| SCHEMBL3027726 | 0.81 | GRIN1 (0.37) | BACE1CTSDGRIN1GRIN2BSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | claimed |
| EP-2209373-B1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2012-05-23 | — | — | EP | claimed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | claimed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | claimed |
| EP-2209373-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | claimed |
| EP-2205079-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009045381-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | BACE1 236/4885CTSD 858/4885MAOB 258/4885 |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | BACE1 236/4885CTSD 858/4885MAOB 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.